ALTEOGEN Inc.

KOSDAQ:A196170 Voorraadrapport

Marktkapitalisatie: ₩19.6t

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

ALTEOGEN Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Soon-Jae Park

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEOno data
Eigendom CEO19.7%
Management gemiddelde ambtstermijn2.8yrs
Gemiddelde ambtstermijn bestuurgeen gegevens

Recente managementupdates

Geen updates

Recent updates

ALTEOGEN's (KOSDAQ:196170) Shareholders Should Assess Earnings With Caution

May 25
ALTEOGEN's (KOSDAQ:196170) Shareholders Should Assess Earnings With Caution

ALTEOGEN (KOSDAQ:196170) Has Debt But No Earnings; Should You Worry?

Feb 29
ALTEOGEN (KOSDAQ:196170) Has Debt But No Earnings; Should You Worry?

ALTEOGEN Inc.'s (KOSDAQ:196170) Has Found A Path To Profitability

Apr 13
ALTEOGEN Inc.'s (KOSDAQ:196170) Has Found A Path To Profitability

Is Weakness In ALTEOGEN Inc. (KOSDAQ:196170) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Feb 18
Is Weakness In ALTEOGEN Inc. (KOSDAQ:196170) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Do Insiders Own Lots Of Shares In ALTEOGEN Inc. (KOSDAQ:196170)?

Dec 27
Do Insiders Own Lots Of Shares In ALTEOGEN Inc. (KOSDAQ:196170)?

CEO

Soon-Jae Park

no data

Tenure

Dr. Soon-Jae Park, Ph D., serves as the Chief Executive Officer of ALTEOGEN Inc. He has several years of experience in R&D of biomedicine. He served as the Executive Officer at BINEX Co., Ltd.He started w...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Soon-Jae Park
Chief Executive Officerno datageen gegevens19.73%
₩ 3.9t
Hang Yeon Kim
CFO & Executive VP2.8yrsgeen gegevensgeen gegevens
Sang Woo Kang
Senior Vice President of Management Support Group2.8yrsgeen gegevensgeen gegevens
Tae-Yon Chun
Executive VP & Corporate Alliance Officer (CAO)4.8yrsgeen gegevensgeen gegevens
Kyuwan Kim
Senior VP & Head of New Drug Developmentno datageen gegevensgeen gegevens
Vivek B Shenoy
Chief Business Development Officer2.8yrsgeen gegevensgeen gegevens

2.8yrs

Gemiddelde duur

Ervaren management: Het managementteam van A196170 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).